Who is sponsoring NCT02559726?

NCT02559726 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT02559726?

Interventions in NCT02559726: Echocardiography (TEE), Magnetic resonance imaging (MRI) with gadolinium enhancement, Magnetic resonance imaging (MRI) without gadolinium enhancement, 3D electrocardiographic mapping (ECM).

What condition does NCT02559726 study?

NCT02559726 studies Hypertrophic Cardiomyopathy, Mechanical Hyper-synchronicity.

Is NCT02559726 still recruiting?

NCT02559726 is currently completed. Last updated 14 February 2022.

Last reviewed 2022-02-14 · How we verify

NCT02559726: HSYNC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyper-synchronicity in Hypertrophic Cardiomyopathy (HCM) : Description, Mechanism and Origin With a Multi-imaging Approach to Predict Dual Chamber Pacing Response

Completed NA Last updated 14 February 2022

What this trial tests

NA trial testing Echocardiography (TEE) in Hypertrophic Cardiomyopathy in 60 participants. Completed in 19 January 2019.

Timeline

22 June 2015

Primary endpoint
19 January 2019

19 January 2019

Quick facts

Lead sponsor	University Hospital, Bordeaux
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	60
Start date	22 June 2015
Primary completion	19 January 2019
Estimated completion	19 January 2019
Sites	1 location across France

Drugs / interventions tested

Echocardiography (TEE)
Magnetic resonance imaging (MRI) with gadolinium enhancement
Magnetic resonance imaging (MRI) without gadolinium enhancement
3D electrocardiographic mapping (ECM)

Conditions studied

Hypertrophic Cardiomyopathy — all drugs for Hypertrophic Cardiomyopathy →
Mechanical Hyper-synchronicity — all drugs for Mechanical Hyper-synchronicity →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Hypertrophic Cardiomyopathy or Mechanical Hyper-synchronicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease. Outflow-tract gradient of 30 mmHg or more under resting conditions is an independent determinant of symptoms of progressive heart failure and death. The investigators hypothesize that the electrical approach by dual chamber pacing could improve symptoms and reduce outflow-tract obstruction in a specific sub-group of selected patients with a mechanical hyper-synchronicity. The aim of the study is to identify and describe this phenomenon in HCM with (O-HCM) and without (NO-HCM) outflow-tract obstruction thanks to innovative multi-imaging approach.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hypersynchrony in sarcomeric hypertrophic cardiomyopathy: description and mechanistic approach using multimodal electro-mechanical non-invasive cartography (HSYNC study).
Réant P, Bonnet G, Dubé F, Massie C, et al · · 2024 · PMID 38911519 · DOI 10.3389/fcvm.2024.1359657

Verify or expand the search:

Other recruiting trials for Hypertrophic Cardiomyopathy

Currently open trials in the same condition.

NCT07361289 — A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopa · recruiting
NCT06490250 — Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients · NA · recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting
NCT06549608 — A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada · active not recruiting
NCT05939700 — Mavacamten Pregnancy Surveillance Program · recruiting

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02559726 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 14 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02559726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing